Showing 7301-7310 of 9828 results for "".
- LEVEL UP: Switching from Dupilumab to Upadacitinib Promising for AD Patientshttps://practicaldermatology.com/news/level-up-switching-from-dupilumab-to-upadacitinib-promising-for-ad-patients/2468483/New research presented at the 44th Annual Fall Clinical Dermatology Conference offered compelling results from th
- Study: Adherence Declines With Complex Atopic Dermatitis Regimenshttps://practicaldermatology.com/news/dherence-declines-complex-atopic-dermatitis-regimens-aad-guidelines/2468194/New American Academy of Dermatology (AAD) guidelines emphasize complex topical regimens for atopic dermatitis (AD), but adherence issues may limit their effectiveness, according to new research. According to a recent article in the Journal of Drugs in Dermatology, the AAD released
- Study: LTX-315 Shows 86% Reduction in BCC Tumor Sizehttps://practicaldermatology.com/news/study-ltx-315-shows-86-reduction-bcc-tumor-size/2467796/Lytix Biopharma has announced promising preliminary results from a phase 2 clinical trial evaluating the efficacy of LTX-315, its candidate drug for the treatment of basal cell carcinoma (BCC). The trial was conducted by Verrica Pharmaceuticals, according to a news release, and the result
- Analysis: Age, Number of Mohs Surgery Stages Linked with Higher-risk Basal Cell Carcinomahttps://practicaldermatology.com/news/analysis-age-number-mohs-surgery-stages-linked-higher-risk-basal-cell-carcinoma/2467270/
- Study Reveals Skin Cancer Surveillance Gaps in Transplant Recipientshttps://practicaldermatology.com/news/study-reveals-skin-cancer-surveillance-gaps-transplant-recipients/2467203/
- Report: Aesthetic Lasers Market to Surge 16.6% Annually Through 2032https://practicaldermatology.com/news/report-aesthetic-lasers-market-surge-166-annually-through-2032/2467086/Markets for aesthetic lasers are projected to $5.392 billion by 2032, according to a new report fro
- Study Links Oral Contraceptives and CYP1B1 Variant to Alopecia Riskhttps://practicaldermatology.com/news/study-links-oral-contraceptives-and-cyp1b1-variant-alopecia-risk/2463230/Recent research published in JAMA Dermatology highlighted a potential linkage between the use of oral contraceptive pills (OCP) and the protective effect of a common missense variant in the CYP1B1 gene on the risk of developing frontal fibrosing alopecia (FFA). Researchers for the case-co
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w
- Allergan Calls for Real Patient Stories in New Campaignhttps://practicaldermatology.com/news/allergan-calls-real-patient-stories-new-campaign/2462879/Allergan Aesthetics has announced that it is inviting consumers to participate in upcoming campaigns for their flagship brands, including BOTOX® Cosmetic, the JUVÉDERM® collection of fillers. Both current and prospective patients can now apply for a chance to feature in future brand promo
- EPI Health Issues Voluntary Recall of Several Products Following Bankruptcyhttps://practicaldermatology.com/news/epi-health-issues-voluntary-recall-several-products-following-bankruptcy/2462869/EPI Health (Novan) is initiating a voluntary recall of various within-expiry human drug products as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products. The moves comes after EPI filed Chapter 7 bankru